Objectives: We evaluated the association between pre-ART HIV DNA and HIV-infected participant characteristics at baseline as well as with their response to first-line ART.
Introduction
HIV-1 is known to establish persistent infection through different mechanisms, the main one being HIV-1 DNA persistence in infected cells, such as CD4! T cells that remain the main contributor to viral persistence and the major obstacle for cure strategies. [1] [2] [3] [4] [5] [6] Several markers have been proposed to measure the viral burden in these cells and among these total HIV DNA is a good candidate due to the simplicity, accuracy and reproducibility of its quantification and the small sample required. [7] [8] [9] [10] [11] Total HIV DNA includes both integrated and unintegrated forms of HIV DNA, which can coexist in infected cells and can actively participate in viral transcription, viral replication and pathogenesis. 12, 13 In the setting of drug-naive patients, total HIV DNA has been shown to be a clinically relevant parameter for disease progression, [14] [15] [16] [17] with a predictive power for AIDS or death stronger than that of plasma HIV RNA. 16 Recent studies also suggest that total HIV DNA can predict the time and magnitude of viral rebound in treatment-experienced patients after therapy interruption, 17 as well as early virological failure in pretreated patients receiving simplified regimens. 18 In the setting of long-term effective ART, total HIV DNA in CD4! T cells not only reflects the size of the replication-competent viral load (VL), 19, 20 but has also been linked to multiple treatment outcomes, such as therapeutic failure, residual viraemia and immune recovery, 21, 22 thus reinforcing the utility of total HIV DNA monitoring in long-term treatment follow-up.
Very limited data are available regarding the prognostic value of pretreatment HIV DNA to predict the chance of virological suppression and of long-term treatment outcome in patients starting their first-line ART regimen. [23] [24] [25] For this reason, this study aims to investigate the association between total HIV DNA (quantified by a modified commercial assay at ART initiation) and other pre-ART viroimmunoclinical parameters, as well as its prognostic value to predict subsequent viral response in patients achieving first viral suppression.
Methods

Study population
This prospective study includes retrospective collected samples from patients belonging to the ICONA Foundation Cohort, a multicentre Italian cohort enrolling and prospectively following ART-naive HIV-infected patients who participated in the original ICONA study. 26 CD4! T cells and CD8! T cell counts and VL measurements were performed on average every 4 months (median 3.4, IQR 2.1-6.0); patients were monitored also for other laboratory parameters (e.g. liver and kidney function, lipids), clinical and treatment data. A biobank collecting plasma and blood cell samples at baseline and yearly is also available.
Our analyses were limited to ART-naive patients who started an ART regimen including at least three antiretroviral drugs after 1 January 2000 and having a clinical and viro-immunological follow-up of at least 1 year. Each patient at ART initiation had available a stored PBMC aliquot and/or whole blood and plasma samples, for HIV DNA and plasma biomarker evaluation, respectively. All patients were also monitored by standard routine visits and evaluated for the development of AIDS, serious non-AIDS events or death. The following diseases were considered serious non-AIDS events: end-stage liver disease, end-stage renal disease, myocardial infarction, sepsis, non-AIDS-defining cancers and severe cardiovascular events.
All patients signed informed consent forms to participate in the ICONA Foundation Study. The research study protocol was approved by local institutional review boards and by the ethics committee of each participating centre.
Quantification of plasma HIV-1 RNA
Depending on methodologies available during 2000-16, plasma HIV RNA was routinely determined using three different assays at the different participating centres. [27] [28] [29] Details are provided in the Supplementary Methods (see Supplementary data at JAC Online).
Quantification of pre-ART HIV DNA
Total HIV DNA was quantified at University of Rome Tor Vergata before ART initiation (time window for HIV DNA collection #12+1 weeks from ART initiation) starting from a pellet of at least 1%10 6 PBMCs (range of 1%10 6 to 6%10 6 ) for 272 patients, and from 200 lL of whole blood for 161 patients, by using a modified version of the commercial COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v2.0, as previously reported. 10 Detailed methodology is provided in the Supplementary data.
Quantification of plasma biomarkers
We used commercially available ELISAs to quantify plasma levels of IL-6 and soluble CD14 (sCD14) (R&D Systems), according to the manufacturer protocols.
Statistical analysis
Patients were ranked in three categories according to a priori chosen cut-offs in the HIV DNA levels at ART initiation (pre-ART HIV DNA): 10-1000 copies/10 6 CD4! T cells; 1000-10 000 copies/10 6 CD4! T cells; and .10 000 copies/10 6 CD4! T cells. Categorical factors at baseline were compared across HIV DNA groups using the v 2 test.
Virological suppression
Standard survival analysis based on Kaplan-Meier estimates was used to evaluate the association between pre-ART HIV DNA levels and the time to achieve virological suppression, defined as the first of two determinations of plasma HIV RNA 50 copies/mL. These analyses were performed on the overall population (n " 433).
Long-term treatment outcome
To evaluate the possible effect of pre-ART HIV DNA levels on the risk of virological rebound, we included in the analysis only participants who had achieved virological suppression 50 copies/mL (n " 397). Standard survival analysis based on Kaplan-Meier estimates was used to evaluate the association between pre-ART HIV DNA and the time to achieve the following primary endpoint: virological rebound, defined according to three different HIV RNA cut-off values: (i) two confirmed plasma HIV RNA determinations .50 copies/mL; (ii) two confirmed plasma HIV RNA determinations .200 copies/mL; and (iii) a single plasma HIV RNA .1000 copies/mL. Secondary endpoints were: (i) an increase in CD4! T cell count of at least 200 cells/mm 3 from pre-ART levels; and (ii) AIDS diagnosis, serious non-AIDS events or death. Kaplan-Meier curves were compared by means of the Fleming-Harrington test.
Cox regression models were used to test the prognostic value of pre-ART HIV DNA (fitted in the log 10 scale) to predict long-term treatment outcomes, after controlling for a number of identified potential confounders. A similar analysis was performed to test the impact of pre-ART HIV RNA on the same outcomes.
A detailed description of the statistical analyses used can be found in the Supplementary data.
Statistical analyses were performed using SAS (version 9.4, SAS Institute, Cary, NC, USA).
Results
Patient characteristics
Four-hundred and thirty-three patients were included in this analysis. Baseline patient characteristics according to HIV DNA strata are shown in Table 1 . The majority were male (n " 350, 80.8%) and MSM (n " 194, 44 .8%). The median age was 38 years (IQR 33-46 years).
Pre-ART HIV DNA influences ART outcome JAC For a subset of individuals (n " 7), for whom both blood samples and PBMCs were available, we performed the total HIV DNA quantification by both sources. Results of HIV DNA quantification normalized for CD4 cells were comparable [median (IQR) HIV DNA was 3.5 (3.2-4.6) log 10 copies/10 6 CD4! T cells in blood samples and 3.7 (3.4-4.7) log 10 copies/10 6 CD4! T cells in PBMCs; P " 0.13]. As per inclusion criteria, all patients were enrolled before ART initiation and had a median plasma HIV RNA and a median HIV DNA of ) log 10 copies/mL and 10 702 (IQR 3397-36 632) copies/10 6 CD4! T cells, respectively. Median CD4! T cell count was 297 (IQR 160-408) cells/mm 3 . The median (IQR) year of sample collection (corresponding to the start of ART) was 2010 (2004-11) . Data regarding ART, time to achieve virological suppression (50 copies/mL) and genotypic susceptibility score (GSS) of ART are shown in Table S1 .
By stratifying patients according to pre-specified clinical cutoffs for pre-ART HIV DNA, more than half of patients (n " 227, 52.4%) had a total HIV DNA higher than .10 000 copies/10 6 CD4! T cells, 37.4% (n " 162) between 1000 and 10 000, and only 10.2% (n " 44) between 10 and 1000 copies/10 6 CD4! T cells. By correlating pre-ART HIV DNA with other viro-immunological parameters, higher plasma HIV RNA (P , 0.0001), lower CD4! T cell count (P , 0.0001) and lower CD4/CD8 ratio (P , 0.0001) at baseline were more frequently observed in the patients with pre-ART HIV DNA 
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.10 000 copies/10 6 CD4! T cells than in those with pre-ART HIV DNA in the ranges 1000-10 000 and 10-1000 copies/10 6 CD4! T cells ( Table 1) . As expected, correlations between higher levels of pre-ART HIV DNA and (i) higher plasma HIV RNA; (ii) lower CD4! T cell count; and (iii) lower CD4/CD8 ratio, all collected at baseline of ART, were confirmed by significant linear correlations (Pearson R 2 and P values: !0.44 and ,0.0001; #0.58 and ,0.0001; and #0.48 and ,0.0001, respectively) ( Figure 1 ). Conversely, less strong correlations were found between HIV DNA and IL-6 (P " 0.002), sCD14 (P " 0.05) and CD8! T cells (P " 0.01) (Figure 1 ).
Role of pre-ART HIV DNA in influencing treatment outcome
Kaplan-Meier curves and Cox regression multivariable analyses were performed to characterize the association between pre-ART HIV DNA and therapy outcomes in our study population.
Association between pre-ART HIV DNA and time to achieve virological suppression 50 copies/mL Of the 433 patients analysed, 397 achieved virological suppression. In particular, the probability of achieving plasma HIV RNA 50 copies/mL by 12 and 24 months after starting ART was 73.6% (95% CI 69.3-77.8) and 92.1% (95% CI 89.4-94.9), respectively. By stratifying patients according to pre-ART HIV DNA levels, we found that the cumulative probability of virological suppression was significantly lower in the group starting ART with the highest HIV DNA (Figure 2 ). In particular, the proportion of patients reaching virological suppression was 67.2% (95% CI 60.9-73.5) in the pre-ART HIV DNA .10 000 copies/10 6 CD4! T cells group, 81.1% (95% CI 75.0-87.3) in the pre-ART HIV DNA 1000-10 000 copies/10 6 CD4! T cells group and 86.4% (95% CI 75. 4-97. 3) in the pre-ART HIV DNA 10-1000 copies/10 6 CD4! T cells group (P " 0.0004 by Fleming-Harrington test). Further, the estimated median time to achieve virological suppression in patients with a pre-ART HIV DNA .10 000 copies/10 6 CD4! T cells was significantly longer than that observed in the remaining two groups [median time to reach virological suppression: 10.0 (IQR 9-11) months for patients with HIV DNA .10 000 copies/10 6 CD4! T cells; 8.0 (IQR 7-9) months for patients with 1000-10 000 copies/10 6 CD4! T cells; and 8.0 (IQR 6-9) months for patients with 10-1000 copies/ 10 6 CD4! T cells] (Figure 2) . Overall, by 6 months of treatment the percentage of patients with HIV RNA 50 copies/mL was low, probably due to a large proportion of patients starting treatment with less potent ART. At 6 and 12 months there was a statistically significant difference in the percentage of patients who were virologically suppressed according to the three different HIV DNA strata [patients with plasma HIV RNA 50 copies/mL at 6 months after starting ART Pre-ART HIV DNA influences ART outcome JAC were 18/42 (43%), 53/153 (35%) and 32/215 (15%), and at 12 months were 31/36 (86%), 127/142 (89%) and 137/198 (69%), respectively, for baseline HIV DNA of 10-1000, 1000-10 000 and .10 000 copies/10 6 CD4! T cells; false discovery rate (FDR) P , 0.0001 at both timepoints].
Association of pre-ART HIV DNA with the virological rebound
By considering the 397 patients achieving virological suppression, the probability of experiencing virological rebound, defined by two confirmed plasma HIV RNA determinations .50 copies/mL, was 12% (95% . By stratifying patients for the three different pre-ART HIV DNA levels, increasing rates of virological rebound were found with increasing pre-ART HIV DNA (P " 0.0048 by Fleming-Harrington test) (Figure 3 ). In particular, by 12 and 24 months the proportion of patients experiencing virological rebound for those with a pre-ART HIV DNA .10 000 copies/10 6 CD4! T cells was significantly higher than that observed in the remaining two patient categories 3) by 12 months and 17.2% (95% CI 11.7-22.6) by 24 months for patients with HIV DNA .10 000 copies/10 6 CD4! T cells; 4.8% (95% CI 1.3-8.2) by 12 months and 7.4% (95% CI 2.9-1.8) by 24 months for patients with 1000-10 000 copies/10 6 CD4! T cells; and 0.0% (95% CI 0.0-0.0) by 12 months and 4.3% (95% CI: 0-12.7) by 24 months for those with 10-1000 copies/10 6 CD4! T cells]. The results were similar using different definitions of virological rebound, such as two confirmed plasma HIV RNA determinations .200 copies/mL or a single HIV RNA determination .1000 copies/mL, even if the P values by Fleming-Harrington tests were not significant (P " 0.20 and P " 0.16, respectively; data not shown).
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increasing levels of pre-ART HIV DNA (P " 0.95 and P " 0.11, by Fleming-Harrington test, respectively; data not shown).
Relative prognostic value of pre-ART HIV DNA and HIV RNA to predict treatment outcome
In order to directly compare the relative prognostic value of pre-ART HIV DNA and pre-ART HIV RNA for virological suppression and long-term virological rebound, first we created a bivariable Cox regression model including only these two factors, both fitted to the log 10 scale (Table 2) . We then proceeded to perform the comparison after controlling for potential confounding factors (three separate sets of confounders) ( Table 3) .
Prognostic value of pre-ART HIV DNA and pre-ART HIV RNA on the chance of virological suppression and risk of developing clinical events By the initial bivariable analysis, higher pre-ART HIV DNA and higher pre-ART HIV RNA were both associated with a lower hazard of virological suppression, the magnitude of the effect being slightly higher for HIV DNA [HR per log 10 increase 0.84 (95% CI 0.72-0.97) and 0.74 (0.64-0.85), respectively] ( Table 2 ). However, after controlling for other confounding factors, only pre-ART HIV RNA remained independently associated with the probability of virological suppression (P , 0.0001 in both models A and B) and weakly associated with the CD4! T cell count recovery (raw P value " 0.028 in model A and 0.011 in model B) ( Table 3) .
Of note, HIV DNA was associated with the risk of AIDS diagnosis or the occurrence of a serious non-AIDS event or death after controlling for HIV RNA alone (Table 2 ), but neither viral parameter was associated with this outcome after further adjusting for the other factors (Table 3) .
Prognostic value of pre-ART HIV DNA and pre-ART HIV RNA on virological rebound
Looking at the risk of virological rebound in people who initially achieved virological suppression, in the bivariable model, only patients with a higher pre-ART HIV DNA were at higher risk of virological rebound, for all definitions of rebound (confirmed .50 copies/mL, confirmed .200 copies/mL or single .1000 copies/mL), (Table 2) . Interestingly, in all three models, with adjustment for other confounding factors, higher pre-ART HIV DNA was confirmed to be the only factor to have a strong prognostic value for viral rebound, whichever definition was applied for it (Table 3) . In particular, when virological rebound was defined as a single determination of plasma HIV RNA .1000 copies/mL or two confirmed plasma determinations of HIV RNA .200 copies/mL, the risk that this event occurred in patients with a pre-ART HIV DNA .1000 copies/10 6 CD4! T cells was more than 2-fold or even 4-fold higher (according to these two virological rebound definitions) than in patients with a pre-ART HIV DNA ,1000 copies/10 6 CD4! T cells. Interestingly, this association was also found using the third model with final adjustment for antiretrovirals being stopped prior to achieving VL 50 copies/mL, time to achieve VL 50 copies/mL, total number of drugs used prior to VL 50 copies/mL and the GSS (Table 3) .
Discussion
In this study, we performed a comprehensive evaluation of the role of pre-ART HIV DNA, defined as the total HIV DNA normalized by CD4! T cell count, in the treatment outcome of patients starting first-line ART. The most important finding of our study is that in people who originally achieved viral suppression 50 copies/mL, pre-ART HIV DNA level was a strong and significant predictor of virological rebound. Indeed, Cox multivariable estimates confirmed that pre-ART HIV DNA/10 6 CD4! T cells, and not pre-ART HIV RNA, was an independent factor associated with faster virological rebound: 1 log 10 HIV DNA higher resulted in a 4-fold higher risk of virological rebound, with an HIV RNA threshold of 200 copies/mL.
So far the predictive value of total HIV DNA in treatment outcomes, such as virological rebound, immune recovery and cell activation status, and also in the setting of de-escalation, has been evaluated in extensively ART-pretreated populations. 7, [17] [18] [19] [20] [21] [22] 31 Few studies have clearly defined the role of total HIV DNA when measured in drug-naive patients before first ART initiation. Previous papers have mainly focused on heterogeneous populations typically of small sample size. [23] [24] [25] 32 For example, a prospective multicentre study has tried to assess the predictive value of PBMC HIV-1 DNA for determining virological and immunological outcomes in a cohort of 148 patients who were treated (starting from 1998) with a first-line PI-containing regimen. This analysis showed that a higher baseline HIV-1 DNA level was associated with an increased risk of virological failure after 1 year of ART, independently of other factors considered. 23 The Monark study showed that, analysing baseline HIV DNA in whole blood using real-time PCR in 46 antiretroviral-naive patients receiving lopinavir/ritonavir monotherapy, the non-responders (with HIV RNA .50 copies/mL) at 48 weeks had significantly higher baseline HIV-1 DNA load than responders (HIV RNA 50 copies/mL). 24 In our analysis, we found a direct association between pre-ART total HIV DNA and the risk of virological rebound, after virological suppression during therapy, in a large cohort of patients starting ART. Moreover, this association was independent of pre-ART plasma HIV RNA and CD4! T cell count, suggesting that HIV DNA contains information related to Hatzakis et al. 25 In that paper, cellular HIV-1 DNA load was the only parameter associated with the chance of achieving sustained virological response in people starting treatment from being ART-naive. In other words, our analysis confirms the role of pre-ART HIV RNA to predict initial virological response to treatment, 17, 33 while diminishing its role as a predictor of viral rebound, once HIV DNA is accounted for.
On the basis of our results, the quantification of HIV DNA levels in CD4! T cells before therapy should be considered, besides what is currently used in the clinics, to help identify people at lower (or higher) risk of viral rebound following achievement of suppression. Our data also provide indirect evidence to guide the choice of first treatment in ART-naive individuals.
For instance, it is known that, compared with other available drug classes, the inclusion of an integrase strand transfer inhibitor (INSTI) in first-line combinations is associated with faster HIV-1 VL decay 34 and a larger reduction of total HIV-1 DNA in virologically suppressed HIV-1-infected patients. 35 On the basis of our results it could be argued that the use of an INSTI is appropriate in patients with high baseline levels of HIV DNA and that their use may have long-term benefits by reducing HIV DNA in people with controlled HIV RNA.
Interestingly, higher levels of pre-ART HIV DNA showed a good correlation with higher levels of several inflammatory markers associated with T cell immune activation, such as IL-6, sCD14 and CD8! T cells, supporting the association between HIV DNA and systemic inflammation, and thus clinical progression. These results are, however, in contrast with a recent paper published by Gandhi et al., 36 showing that levels of HIV DNA (pre-ART and during therapy) are not associated with different levels of inflammatory biomarkers such as IL-6, sCD14 and sCD163. Because of these conflicting findings, studies including higher numbers of patients will be necessary to estimate the real role of HIV DNA in the inflammatory process and thus to better understand the role of this parameter in the definition of the inflammatory process and thus clinical progression.
In addition, it needs to be noted that, to date, the major problem with measuring HIV DNA is the lack of reproducibility of different tests and different samples used for the analysis. Currently, there are different in-house protocols to quantify HIV DNA starting from CD4! T cells, PBMC or whole blood, by measuring total HIV DNA, proviral-integrated or two long terminal repeats (2 LTRs) and few commercial assays (so far there is a commercial kit 'Generic HIV DNA Cell' from Biocentric, Bandol, France, largely used in France, and another recently developed from Diatheva, HIV-1 DNA qPCR kit, for research use only). For our analysis we used a modified Adjusted for calendar year of ART, type of regimen started, CD4 count, RNA/DNA at ART, age, smoking, HCV status, IL-6 and sCD14. c Adjusted for calendar year of ART, type of regimen started, CD4 count, RNA/DNA at ART, age, smoking, HCV status, whether person had stopped antiretrovirals prior to achieving VL 50 copies/mL, time to achieve VL 50 copies/mL, total number of drugs used prior to baseline and HIV database GSS of baseline regimen.
Pre-ART HIV DNA influences ART outcome JAC commercial assay measuring both integrated, long-lived proviral DNA and unintegrated short-lived HIV DNA. 10 Unlike the other assays described in this paragraph, this assay is simple and may be routinely applied, because it is already largely used in clinical practice for HIV RNA measurement all over the world.
A possible limitation of our analysis is the lack of adherence data, which is a known determinant of virological response to ART, particularly in the presence of larger reservoir sizes. On the other hand, it is unlikely that adherence level is associated with HIV DNA burden in individual patients before starting ART. Of note, the analysis of the risk of viral rebound is restricted to people who did achieve viral suppression 50 copies/mL on ART. When we compared the characteristics of people who ever achieved HIV RNA 50 copies/mL (included in the time to rebound analysis) and those who never achieved viral suppression (excluded), we found that included patients were more likely to be hepatitis-negative, MSM and of Italian origin (Table S2 ). These data confirm that patients evaluated for time to viral rebound analysis were a selected population of participants who are more likely to be adherent to treatment. Therefore, selection bias cannot be ruled out and it needs to be acknowledged that the results of our main analysis are only applicable to populations presumed to have good adherence to treatment.
In conclusion, pre-ART HIV DNA showed strong clinical relevance as a marker of HIV burden and reservoir and, although it is unable to distinguish between replication-competent and replication-defective viral forms, it appears to be useful to predict the course of the infection and also under-exposure to ART. Measurement of HIV DNA while a person is still untreated should be considered both to inform treatment choices and help predict the long-term efficacy of ART. Moreover, in the absence of other sensitive and reproducible tests, because the assay used in our analysis is simple, rapid and easily obtainable on the market, it stands as a promising candidate for standardization and measurement of the HIV reservoir in clinical practice.
